TY - JOUR
T1 - Ixazomib for the treatment of multiple myeloma
AU - Richardson, Paul G.
AU - Zweegman, Sonja
AU - O’Donnell, Elizabeth K.
AU - Laubach, Jacob P.
AU - Raje, Noopur
AU - Voorhees, Peter
AU - Ferrari, Renda H.
AU - Skacel, Tomas
AU - Kumar, Shaji K.
AU - Lonial, Sagar
N1 - Funding Information:
The authors would like to acknowledge the writing support of Jane Saunders of FireKite, an Ashfield company, part of UDG Healthcare plc, in the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Funding Information:
This manuscript is funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Funding Information:
PG Richardson reports research funding from Millennium Pharmaceuticals, Inc. and Celgene. He is also on the advisory committees of Celgene, Janssen Pharmaceuticals, Amgen Inc, and Millennium Pharmaceuticals, Inc. S Zweegman received grant support from, and participated in the advisory boards of, Millennium Pharmaceuticals, Inc. during the conduct of this study, and has received grants from and has served on the advisory boards and speakers’ bureaus of Janssen Pharmaceuticals, and Celgene. She also has participated on an advisory board for Amgen Inc. E O’Donnell has acted as a consultant for Millennium Pharmaceuticals, Inc. J Laubach reports research funding from Millennium Pharmaceuticals, Inc. N Raje has acted as a consultant for Onyx, Amgen Inc, Millennium Pharmaceuticals, Inc., and Celgene. P Voorhees has served on the advisory boards or speakers’ bureaus of Bristol-Myers Squibb, Celgene, Amgen, Janssen Pharmaceuticals, Millennium Pharmaceuticals, Inc. and Oncopeptides, and has consulted for Novartis and Oncopeptides. R Ferrari and T Skacel are employed by Millennium Pharmaceuticals, Inc., and T Skacel is also affiliated with the Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic. S Kumar reports grant support from AbbVie, Celgene, Janssen Pharmaceuticals, Merck & Co, Novartis, Roche, Sanofi, KITE Pharma, and Millennium Pharmaceuticals, Inc. Finally, S Lonial declares that he has acted as a consultant for Millennium Pharmaceuticals, Celgene, Novartis, Amgen, Bristol-Myers Squibb, and Janssen Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing assistance was utilized in the production of this manuscript and funded by Millennium Pharmaceuticals.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/11/22
Y1 - 2018/11/22
N2 - Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral administration and treatment-related toxicities. Ixazomib, the first oral PI to enter the clinic, is approved around the world, in combination with lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. Areas covered: This review summarizes the clinical data leading to approval of ixazomib; its pharmacology, efficacy, and safety. Building on the data in relapsed/refractory MM (RRMM), it also reviews the available clinical trial data for ixazomib across the MM treatment algorithm in newly diagnosed MM, RRMM, and as maintenance therapy, and looks ahead to ongoing clinical trials and the expanding role of ixazomib in these indications. Expert opinion: Ixazomib is an efficacious and well-tolerated addition to the treatment armamentarium for RRMM, with benefit as a long-term, continuous therapy for all patients, including ‘poor prognosis’ patients, such as those with advanced stage disease, high-risk cytogenetic abnormalities, and elderly and frail patients. Data from ongoing clinical studies are expected to expand the role of ixazomib across the MM treatment algorithm and in a broader range of combination regimens.
AB - Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral administration and treatment-related toxicities. Ixazomib, the first oral PI to enter the clinic, is approved around the world, in combination with lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. Areas covered: This review summarizes the clinical data leading to approval of ixazomib; its pharmacology, efficacy, and safety. Building on the data in relapsed/refractory MM (RRMM), it also reviews the available clinical trial data for ixazomib across the MM treatment algorithm in newly diagnosed MM, RRMM, and as maintenance therapy, and looks ahead to ongoing clinical trials and the expanding role of ixazomib in these indications. Expert opinion: Ixazomib is an efficacious and well-tolerated addition to the treatment armamentarium for RRMM, with benefit as a long-term, continuous therapy for all patients, including ‘poor prognosis’ patients, such as those with advanced stage disease, high-risk cytogenetic abnormalities, and elderly and frail patients. Data from ongoing clinical studies are expected to expand the role of ixazomib across the MM treatment algorithm and in a broader range of combination regimens.
KW - Efficacy
KW - ixazomib
KW - multiple myeloma
KW - proteasome inhibitor
KW - tolerability
UR - http://www.scopus.com/inward/record.url?scp=85057548260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057548260&partnerID=8YFLogxK
U2 - 10.1080/14656566.2018.1528229
DO - 10.1080/14656566.2018.1528229
M3 - Article
C2 - 30422008
AN - SCOPUS:85057548260
VL - 19
SP - 1949
EP - 1968
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 17
ER -